Moreover, the use of FDA-approved SGLT2 inhibitors significantly inhibited tumor growth and prolonged survival in lung cancer models, suggesting that SGLT2 could serve not only as a diagnostic marker but also as a therapeutic target for early-stage lung cancer. Here, SLC5A2 is linked to neoplasm.